Trachoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Trachoma}} | {{Trachoma}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
{{CMG}} | {{CMG}} | ||
| Line 17: | Line 20: | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Needs content]] | |||
[[Category:Needs | |||
Revision as of 15:27, 12 December 2012
|
Trachoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Trachoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Trachoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Trachoma cost-effectiveness of therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.